European Commission Approves BRUKINSA® (zanubrutinib) for the Treatment of R/R Follicular Lymphoma November 29, 2023
Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL in the European Union October 25, 2023
EC Approves ADCETRIS + AVD combo for Adult Patients with 1L CD30+ Stage III Hodgkin Lymphoma October 25, 2023
US FDA places lacutamab IND on partial clinical hold for new patient enrollment following one unexpected severe adverse reaction October 11, 2023
U.S. FDA Fast Track Designation for KT-333 for the Treatment of R/R Cutaneous T-Cell Lymphoma and R/R Peripheral T-Cell Lymphoma October 11, 2023
Odronextamab BLA for Treatment of R/R Follicular Lymphoma (FL) and DLBCL Accepted for FDA Priority Review October 3, 2023
European Commission Approves Enrylaze for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma October 3, 2023
First Patient dosed in Ph 1/2 Trial of IMPT-314 for the Treatment of Aggressive B-cell Lymphoma September 26, 2023
Yescarta Demonstrates High Response Rate And Durable Remission In ALYCANTE Study As Initial Treatment For Transplant-Ineligible Patients With R/R LBCL September 26, 2023
U.S. FDA Fast Track Designation for KT-333 for the Treatment of R/R Cutaneous T-Cell Lymphoma and R/R Peripheral T-Cell Lymphoma September 26, 2023
Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL) September 19, 2023
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study September 13, 2023
First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy Announced August 23, 2023
FDA sends CRL for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with R/R CTCL August 9, 2023
Ph 2 LOTIS-9 Trial of ZYNLONTA (loncastuximab tesirine-lpyl) and Rituximab in Unfit/Frail 1L DLBCL Patients to be discontinued August 2, 2023
Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with R/R DLBCL July 27, 2023
Voluntary Pause of Enrollment in Ph 2 LOTIS-9 Trial of ZYNLONTA (loncastuximab tesirine-lpyl) and Rituximab in Unfit/Frail 1L DLBCL Patients Announced July 19, 2023
Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL reported July 19, 2023
Supplemental NDA submitted to FDA for BRUKINSA + obinutuzumab in R/R follicular lymphoma July 19, 2023
